[go: up one dir, main page]

MX2018002241A - Combinaciones y sus usos. - Google Patents

Combinaciones y sus usos.

Info

Publication number
MX2018002241A
MX2018002241A MX2018002241A MX2018002241A MX2018002241A MX 2018002241 A MX2018002241 A MX 2018002241A MX 2018002241 A MX2018002241 A MX 2018002241A MX 2018002241 A MX2018002241 A MX 2018002241A MX 2018002241 A MX2018002241 A MX 2018002241A
Authority
MX
Mexico
Prior art keywords
combinations
antibody
inhibitor
present disclosure
treatment
Prior art date
Application number
MX2018002241A
Other languages
English (en)
Other versions
MX392561B (es
Inventor
Boxhammer Rainer
Endell Jan
Winderlich Mark
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2018002241A publication Critical patent/MX2018002241A/es
Publication of MX392561B publication Critical patent/MX392561B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

La presente divulgación describe una combinación farmacéutica de un anticuerpo anti-CD19 y un inhibidor de fosfoinositida 3-quinasa para el tratamiento de linfoma no Hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
MX2018002241A 2015-08-21 2016-08-18 Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda. MX392561B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15181925 2015-08-21
PCT/EP2016/069571 WO2017032679A1 (en) 2015-08-21 2016-08-18 Combinations and uses thereof

Publications (2)

Publication Number Publication Date
MX2018002241A true MX2018002241A (es) 2018-03-23
MX392561B MX392561B (es) 2025-03-24

Family

ID=54010888

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018002241A MX392561B (es) 2015-08-21 2016-08-18 Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
MX2022006154A MX2022006154A (es) 2015-08-21 2018-02-20 Combinaciones y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006154A MX2022006154A (es) 2015-08-21 2018-02-20 Combinaciones y sus usos.

Country Status (23)

Country Link
US (3) US11224654B2 (es)
EP (2) EP3337506B1 (es)
JP (4) JP6862422B2 (es)
KR (2) KR20180042335A (es)
CN (2) CN107921129B (es)
AU (3) AU2016311136B2 (es)
CA (1) CA2995738A1 (es)
CY (1) CY1124706T1 (es)
DK (1) DK3337506T3 (es)
ES (1) ES2891336T3 (es)
HR (1) HRP20211291T1 (es)
HU (1) HUE056408T2 (es)
IL (2) IL257345B2 (es)
LT (1) LT3337506T (es)
MX (2) MX392561B (es)
PL (1) PL3337506T3 (es)
PT (1) PT3337506T (es)
RS (1) RS62260B1 (es)
RU (1) RU2767063C2 (es)
SI (1) SI3337506T1 (es)
SM (1) SMT202100541T1 (es)
WO (1) WO2017032679A1 (es)
ZA (1) ZA201801052B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) * 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
LT3532098T (lt) 2016-10-28 2021-06-25 Morphosys Ag Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas
WO2018220040A1 (en) 2017-05-31 2018-12-06 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル－ドラッグ－ディベロップメント－バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN114786723A (zh) * 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
CA3203587A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
KR20240131370A (ko) * 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
JP2004508420A (ja) 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20080152649A1 (en) * 2002-03-01 2008-06-26 Xencor, Inc. Optimized igf-1r antibodies and methods of using the same
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
RS53263B (sr) * 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US20120128586A1 (en) 2009-06-24 2012-05-24 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
PT2493503E (pt) * 2009-10-27 2015-11-12 Amgen Res Munich Gmbh Regime de dosagem para administração de um anticorpo biespecífico cd19xcd3
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
WO2012054748A2 (en) * 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
PL2744826T3 (pl) 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i analogiem puryny
KR20200058583A (ko) 2011-08-16 2020-05-27 모르포시스 아게 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
CA2900658A1 (en) 2013-02-15 2014-08-21 3M Innovative Properties Company System and method for making pleated filter media
CN106794231A (zh) 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病（cll）的治疗
HUE046328T2 (hu) 2015-05-26 2020-03-30 Morphosys Ag CD19 elleni ellenanyag és Bruton-féle tirozin-kináz gátlójának kombinációja és a kombináció alkalmazásai
AU2016311136B2 (en) * 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
PT3916392T (pt) 2016-05-30 2024-06-04 Incyte Corp Métodos para prever o benefício terapêutico da terapia anti-cd19 nos pacientes
HRP20210945T1 (hr) 2016-06-27 2021-09-17 Morphosys Ag Formulacije protutijela anti-cd19
LT3532098T (lt) 2016-10-28 2021-06-25 Morphosys Ag Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas
WO2018220040A1 (en) 2017-05-31 2018-12-06 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MA55794A (fr) 2019-05-03 2022-03-09 Morphosys Ag Thérapie anti-cd19 chez des patients ayant un nombre limité de cellules nk
KR20220103969A (ko) 2019-10-31 2022-07-25 모르포시스 아게 백혈병 또는 림프종의 치료를 위해 레날리도마이드와 조합된 항-cd19 요법
AU2020372646A1 (en) 2019-10-31 2022-05-12 Incyte Corporation Anti-tumor combination therapy comprising anti-CD19 antibody and gamma delta T-cells
CN114786723A (zh) 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
JP2023530499A (ja) 2020-06-22 2023-07-18 モルフォシス・アーゲー 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法
CA3203587A1 (en) 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
BR112023010885A2 (pt) 2020-12-04 2023-10-03 Incyte Corp Terapia de combinação de anti-cd19
KR20240131370A (ko) 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임

Also Published As

Publication number Publication date
HRP20211291T1 (hr) 2021-12-10
IL257345A (en) 2018-03-29
JP2018523685A (ja) 2018-08-23
WO2017032679A1 (en) 2017-03-02
CA2995738A1 (en) 2017-03-02
AU2016311136A1 (en) 2018-03-01
RS62260B1 (sr) 2021-09-30
CN115054697A (zh) 2022-09-16
SI3337506T1 (sl) 2021-12-31
IL257345B2 (en) 2023-03-01
NZ739706A (en) 2025-02-28
CN107921129A (zh) 2018-04-17
RU2018107929A3 (es) 2020-01-14
AU2024202109A1 (en) 2024-05-02
BR112018003263A2 (pt) 2018-09-25
JP2025131697A (ja) 2025-09-09
US20220088197A1 (en) 2022-03-24
LT3337506T (lt) 2021-10-11
IL297057B1 (en) 2025-07-01
IL297057A (en) 2022-12-01
US12194095B2 (en) 2025-01-14
CN115054697B (zh) 2024-06-11
DK3337506T3 (da) 2021-09-06
KR20240052084A (ko) 2024-04-22
MX392561B (es) 2025-03-24
EP3337506B1 (en) 2021-07-21
CY1124706T1 (el) 2022-07-22
IL297057B2 (en) 2025-11-01
AU2022202800A1 (en) 2022-05-19
MX2022006154A (es) 2022-10-07
AU2022202800B2 (en) 2024-01-04
EP3954388A1 (en) 2022-02-16
JP2021113194A (ja) 2021-08-05
IL257345B (en) 2022-11-01
HK1247122A1 (zh) 2018-09-21
KR20180042335A (ko) 2018-04-25
PT3337506T (pt) 2021-09-24
JP2023093495A (ja) 2023-07-04
US20180228893A1 (en) 2018-08-16
AU2016311136B2 (en) 2022-02-17
US20250195646A1 (en) 2025-06-19
CN107921129B (zh) 2022-05-27
KR102786010B1 (ko) 2025-03-26
US11224654B2 (en) 2022-01-18
HUE056408T2 (hu) 2022-02-28
JP6862422B2 (ja) 2021-04-21
ZA201801052B (en) 2021-05-26
RU2018107929A (ru) 2019-09-23
SMT202100541T1 (it) 2021-11-12
RU2767063C2 (ru) 2022-03-16
ES2891336T3 (es) 2022-01-27
PL3337506T3 (pl) 2022-01-03
EP3337506A1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
MX2018002241A (es) Combinaciones y sus usos.
IL271266A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
CY1124648T1 (el) Συνδυασμος αντισωματος αντι- cd19 με εναν αναστολεα bcl-2 και χρησεις αυτου
DOP2017000150A (es) Anticuerpos anti-cd 38 para el tratamiento de leucemia mieloides aguda
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
CY1122298T1 (el) Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του
CO2017006740A2 (es) Anticuerpos anti–cd79b
EP3485366A4 (en) ADAPTIVE SIMULTANEITY FOR WRITING PERSISTENCE
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CR20150667S (es) Portador, bandeja, abrazadera y perilla
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
WO2015190867A3 (ko) 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
BR112015019924A2 (pt) métodos e composições para tratar leucemia
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
EP3475973A4 (en) INTERCONNECT HOLE BLOCKING LAYER
MX2017003344A (es) Composicion de polimero para capa de un elemento de capa.
EP3662784C0 (en) TOOLBOX
CL2019003456A1 (es) Copolimero de etileno que tiene propiedades de película mejoradas.
TR201909125T4 (tr) Yüzey temi̇zlemek i̇çi̇n bi̇r aparat
MX2019002673A (es) Composiciones y metodos para tratar demencia.
MX373056B (es) Formas cristalinas de glecaprevir.
EP3559395A4 (en) STAGE REDUCTION OF ANNULAR SPACE FOR PRESSURE CONTROLLED DRILLING
MX376367B (es) Activacion del factor x.